A.R.T. Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

A.R.T. Advisors’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-26,613	Closed	-$23K	–	1917
2019 Q2	$23K	Sell	26,613 -3,442	-11%	-$3.18K	﹤0.01%	1291
2019 Q1	$29K	Sell	30,055 -2,175	-7%	-$2.29K	﹤0.01%	1244
2018 Q4	$24K	Buy	+32,230	New	+$53K	﹤0.01%	1248
2018 Q2	–	Sell	-13,312	Closed	-$51K	–	1993
2018 Q1	$51K	Buy	+13,312	New	+$46.8K	﹤0.01%	1401
2015 Q4	–	Sell	-16,674	Closed	-$243K	–	1957
2015 Q3	$243K	Hold	16,674	–	–	0.01%	1109
2015 Q2	$325K	Buy	16,674 +15,070	+940%	+$291K	0.01%	1157
2015 Q1	$29K	Buy	+1,604	New	+$36.1K	﹤0.01%	1373

Other funds holding CTIC

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

A.R.T. Advisors's CTIC Position: Q3 2019 in Review

A.R.T. Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q3 2019, closing a stake of 26,613 shares — an estimated $23K sold.

A.R.T. Advisors first reported a position in CTIC in Q1 2015 and held it in 7 quarters. The position peaked at $325K in Q2 2015. 43 funds tracked by Wall St. Rank hold CTIC as of Q3 2019.

A.R.T. Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q3 2019 after selling out during the quarter.
A.R.T. Advisors sold 26,613 CTI BioPharma Corp. (DE) Common Stock shares in Q3 2019, an estimated $23K.
A.R.T. Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2015 and held it in 7 quarters.
A.R.T. Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $325K in Q2 2015.
43 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q3 2019.

Based on A.R.T. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.